Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Impedimed Limited ( (AU:IPD) ) has provided an announcement.
Impedimed Limited has announced the issuance of 1,100,901 fully paid ordinary shares to its executives as part of their remuneration for the quarter ending June 30, 2025. This move, under the Executive Share Plan, reflects the company’s strategy to align executive compensation with company performance, potentially impacting its financial structure and stakeholder interests.
The most recent analyst rating on (AU:IPD) stock is a Buy with a A$0.20 price target. To see the full list of analyst forecasts on Impedimed Limited stock, see the AU:IPD Stock Forecast page.
More about Impedimed Limited
Impedimed Limited operates in the medical technology industry, focusing on providing innovative solutions for the measurement of body composition and fluid status. The company is known for its bioimpedance spectroscopy devices, which are used in various healthcare settings to aid in the management of conditions such as lymphedema and heart failure.
Average Trading Volume: 2,702,662
Technical Sentiment Signal: Hold
Current Market Cap: A$103.4M
Learn more about IPD stock on TipRanks’ Stock Analysis page.